{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:36:18Z","timestamp":1780472178585,"version":"3.54.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,12,25]],"date-time":"2018-12-25T00:00:00Z","timestamp":1545696000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>Despite the widespread clinical use of MTX in PsA, data from published randomized controlled studies suggest limited efficacy. The objective of the present study was to document the efficacy of MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an open-label, prospective study of patients satisfying the ClASsification criteria for Psoriatic ARthritis study (CASPAR) criteria for PsA who received MTX in doses of \u2a7e15 mg\/week throughout the follow-up period of 9 months. Disease activity was assessed across various domains by tender and swollen joint count, physician and patient global assessment, DAS-28 ESR, Clinical Disease Activity Index for PsA (cDAPSA), Leeds Dactylitis Instrument basic, Leeds Enthesitis Index (LEI), Psoriasis Area and Severity Index (PASI), Minimal Disease Activity and HAQ (CRD Pune version) at baseline and at 3, 6 and 9 months of follow-up. Response to therapy was assessed by EULAR DAS28 ESR, Disease Activity Index for PsA (cDAPSA) response, HAQ response and PASI75. MTX dose escalation and the use of combination DMARDS were dictated by disease activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 73 patients were included, with mean (s.d.) age 44 (9.7) years. The mean (s.d.) dose of MTX used was 17.5 (3.8) mg\/week. Seven patients received additional DMARDS (LEF\/SSZ). At the end of 9 months, significant improvement (P &lt; 0.05) was noted in the tender joint count, swollen joint count, global activity, DAS-28ESR, cDAPSA, Leeds Dactylitis Index basic, LEI, PASI and HAQ. Major cDAPSA response was achieved in 58.9% of patients. EULAR DAS28 moderate and good response was achieved in 74% and 6.8% of patients, respectively. Minimal Disease Activity was achieved in 63% of patients. A PASI75 response and HAQ response was achieved in 67.9% and 65.8% of patients, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>MTX initiated at \u2a7e15 mg\/week with targeted escalation resulted in significant improvement in the skin, joint, dactylitis, enthesitis and functional domains of PsA.<\/jats:p><\/jats:sec>","DOI":"10.1093\/rheumatology\/key369","type":"journal-article","created":{"date-parts":[[2018,11,3]],"date-time":"2018-11-03T12:08:38Z","timestamp":1541246918000},"page":"869-873","source":"Crossref","is-referenced-by-count":16,"title":["Methotrexate achieves major cDAPSA response, and improvement in dactylitis and functional status in psoriatic arthritis"],"prefix":"10.1093","volume":"58","author":[{"given":"Sravan Kumar","family":"Appani","sequence":"first","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Nizam\u2019s Institute of Medical Sciences, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phani Kumar","family":"Devarasetti","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Nizam\u2019s Institute of Medical Sciences, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajendra Vara Prasad","family":"Irlapati","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Nizam\u2019s Institute of Medical Sciences, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza","family":"Rajasekhar","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology and Rheumatology, Nizam\u2019s Institute of Medical Sciences, Hyderabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,12,24]]},"reference":[{"key":"2019081609505039700_key369-B1","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s11926-013-0316-4","article-title":"Psoriatic arthritis: phenotypic variance and nosology","volume":"15","author":"Eder","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2019081609505039700_key369-B2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019081609505039700_key369-B3","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised, controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"2019081609505039700_key369-B4","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2019081609505039700_key369-B5","first-page":"1745","article-title":"Development of an assessment tool for dactylitis in patients with psoriatic arthritis","volume":"32","author":"Helliwell","year":"2005","journal-title":"J Rheumatol"},{"key":"2019081609505039700_key369-B6","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Care Res"},{"key":"2019081609505039700_key369-B7","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019081609505039700_key369-B8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.injr.2012.04.009","article-title":"Validation and usefullness of Indian version (CRD Pune) health assessment questionnaire: drug trials, community practice and COPCORD Bhigwan population study (1994\u20132012)","volume":"7","author":"Chopra","year":"2012","journal-title":"Indian J Rheumatol"},{"key":"2019081609505039700_key369-B9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2019081609505039700_key369-B10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.3899\/jrheum.110546","article-title":"Minimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfaction","volume":"38","author":"Mease","year":"2011","journal-title":"J Rheumatol"},{"key":"2019081609505039700_key369-B11","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/ard.2009.113308","article-title":"Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patientswith rheumatoid arthritis","volume":"69","author":"Lie","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2019081609505039700_key369-B12","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatology"},{"key":"2019081609505039700_key369-B13","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.1964.03070100037007","article-title":". Methotrexate therapy in psoriatic arthritis: doubleblind study on 21 patients","volume":"189","author":"Black","year":"1964","journal-title":"JAMA"},{"key":"2019081609505039700_key369-B14","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2019081609505039700_key369-B15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2019081609505039700_key369-B16","doi-asserted-by":"crossref","first-page":"356","DOI":"10.3899\/jrheum.150614","article-title":"Methotrexate efficacy in the Tight Control in Psoriatic arthritis (TICOPA) study","volume":"43","author":"Coates","year":"2016","journal-title":"J Rheumatol"},{"key":"2019081609505039700_key369-B17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.3899\/jrheum.130163","article-title":"Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era","volume":"40","author":"Gladman","year":"2013","journal-title":"J Rheumatol"},{"key":"2019081609505039700_key369-B18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2019081609505039700_key369-B19","first-page":"469","article-title":"Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort","volume":"35","author":"Chandran","year":"2008","journal-title":"J Rheumatol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/58\/5\/869\/28720191\/key369.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T01:18:53Z","timestamp":1720747133000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/58\/5\/869\/5259344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,24]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,12,24]]},"published-print":{"date-parts":[[2019,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/key369","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,5]]},"published":{"date-parts":[[2018,12,24]]}}}